Improvement of Self-Injury With Dopamine and Serotonin Replacement Therapy in a Patient With a Hemizygous PAK3 Mutation: A New Therapeutic Strategy for Neuropsychiatric Features of an Intellectual Disability Syndrome

J Child Neurol. 2018 Jan;33(1):106-113. doi: 10.1177/0883073817740443.

Abstract

PAK3-related intellectual disability is caused by mutations in the gene encoding the p21-activated kinase (PAK) protein. It is characterized by mild to moderate cognitive impairment, micro/normocephaly, and a neurobehavioral phenotype characterized by short attention span, anxiety, restlessness, aggression, and self-abusive behaviors. The authors report a patient with a novel PAK3 mutation, who presented with intellectual disability, severe automutilation, and epilepsy. His magnetic resonance imaging changes were most likely secondary to lacerations from parenchymal contusions. His behavior was difficult to manage with behavior interventions or multiple medications. After finding low levels of dopamine and borderline low serotonin metabolites in the spinal fluid, treatment with low dose L-dopa/carbidopa and 5-hydroxytryptophan significantly improved his self-injurious behavior. This is the first case of PAK3-related intellectual disability presenting with severe self-injury with improvement following treatment. The patient's response to neurotransmitter replacement therapy raises the question if this treatment intervention might help other individuals suffering genetic syndromes and self-injurious behaviors.

Keywords: 5-hydroxytryptophan; L-dopa; cerebrospinal fluid neurotransmitters; homovanillic acid; self-injury.

Publication types

  • Case Reports

MeSH terms

  • 5-Hydroxytryptophan / therapeutic use*
  • Adolescent
  • Brain / diagnostic imaging
  • Carbidopa / therapeutic use*
  • Dopamine / metabolism
  • Drug Combinations
  • Humans
  • Intellectual Disability / diagnostic imaging
  • Intellectual Disability / drug therapy
  • Intellectual Disability / genetics
  • Intellectual Disability / physiopathology*
  • Levodopa / therapeutic use*
  • Male
  • Mutation
  • Psychotropic Drugs / therapeutic use*
  • Self-Injurious Behavior / diagnostic imaging
  • Self-Injurious Behavior / drug therapy*
  • Self-Injurious Behavior / genetics
  • Self-Injurious Behavior / physiopathology*
  • Serotonin / metabolism
  • Syndrome
  • p21-Activated Kinases / genetics

Substances

  • Drug Combinations
  • Psychotropic Drugs
  • carbidopa, levodopa drug combination
  • Serotonin
  • Levodopa
  • 5-Hydroxytryptophan
  • PAK3 protein, human
  • p21-Activated Kinases
  • Carbidopa
  • Dopamine